Literature DB >> 18674871

Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients.

Jesse J Suh1, Daniel D Langleben, Ronald N Ehrman, Jonathan G Hakun, Ze Wang, Yin Li, Samantha I Busch, Charles P O'Brien, Anna Rose Childress.   

Abstract

BACKGROUND: Clinically depressed patients without substance use disorders, compared to controls, exhibit significantly lower resting regional cerebral blood flow (rCBF) in the prefrontal cortex (PFC). In this study, we examined the link between resting rCBF in the PFC and current depressive symptoms in methadone-maintained opiate-dependent (MM) patients with or without major depression.
METHODS: Arterial spin labeled perfusion fMRI at 3 Tesla was used to measure resting rCBF in 21 MM patients. Perfusion data were analyzed using SPM2. The relationship between Beck Depression Inventory (BDI) score and resting rCBF was examined in a single regression analysis.
RESULTS: The BDI scores ranged between 0 and 18 (m=7.0, S.D.=4.8), and 30% of the sample had mild to moderate depression symptoms according to BDI scores. A negative correlation was observed between BDI scores and relative rCBF in the bilateral ventrolateral prefrontal cortex, and middle frontal gyri.
CONCLUSIONS: The inverse relationship between prefrontal paralimbic rCBF and depression scores suggests a link between reduced fronto-limbic activity and depressive symptoms in MM patients. A significant subgroup of opiate-dependent patients has clinical or sub-clinical depression that is often undetected; our data identify brain substrates of depression symptoms that may also be a potential marker of relapse in this population. Treatment strategies targeting these brain regions may improve outcomes in depressed substance abusers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18674871      PMCID: PMC2673981          DOI: 10.1016/j.drugalcdep.2008.06.007

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  60 in total

Review 1.  Etiology of early age onset substance use disorder: a maturational perspective.

Authors:  R Tarter; M Vanyukov; P Giancola; M Dawes; T Blackson; A Mezzich; D B Clark
Journal:  Dev Psychopathol       Date:  1999

2.  Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction.

Authors:  C C Meltzer; M N Cantwell; P J Greer; D Ben-Eliezer; G Smith; G Frank; W H Kaye; P R Houck; J C Price
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

3.  Automated Talairach atlas labels for functional brain mapping.

Authors:  J L Lancaster; M G Woldorff; L M Parsons; M Liotti; C S Freitas; L Rainey; P V Kochunov; D Nickerson; S A Mikiten; P T Fox
Journal:  Hum Brain Mapp       Date:  2000-07       Impact factor: 5.038

4.  Experimental design and the relative sensitivity of BOLD and perfusion fMRI.

Authors:  G K Aguirre; J A Detre; E Zarahn; D C Alsop
Journal:  Neuroimage       Date:  2002-03       Impact factor: 6.556

5.  Neural activity associated with cognitive regulation in heroin users: A fMRI study.

Authors:  Tatia M C Lee; Wen-Hua Zhou; Xiao-Jing Luo; Kenneth S L Yuen; Xin-Zhong Ruan; Xu-Chu Weng
Journal:  Neurosci Lett       Date:  2005-04-20       Impact factor: 3.046

6.  Depression among needle exchange program and methadone maintenance clients.

Authors:  R S Brienza; M D Stein; M Chen; A Gogineni; M Sobota; J Maksad; P Hu; J Clarke
Journal:  J Subst Abuse Treat       Date:  2000-06

7.  Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression.

Authors:  Robert T Dunn; Tim A Kimbrell; Terence A Ketter; Mark A Frye; Mark W Willis; David A Luckenbaugh; Robert M Post
Journal:  Biol Psychiatry       Date:  2002-03-01       Impact factor: 13.382

8.  Neuroimaging studies of mood disorders.

Authors:  W C Drevets
Journal:  Biol Psychiatry       Date:  2000-10-15       Impact factor: 13.382

9.  Effects of major depression on remission and relapse of substance dependence.

Authors:  Deborah Hasin; Xinhua Liu; Edward Nunes; Steven McCloud; Sharon Samet; Jean Endicott
Journal:  Arch Gen Psychiatry       Date:  2002-04

10.  Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers.

Authors:  E F Domino; S Minoshima; S K Guthrie; L Ohl; L Ni; R A Koeppe; D J Cross; J Zubieta
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

View more
  6 in total

1.  Regional cerebral blood flow in opiate dependence relates to substance use and neuropsychological performance.

Authors:  Donna E Murray; Timothy C Durazzo; Thomas P Schmidt; Troy A Murray; Christoph Abé; Joseph Guydish; Dieter J Meyerhoff
Journal:  Addict Biol       Date:  2017-06-19       Impact factor: 4.280

Review 2.  Prefrontal-accumbens opioid plasticity: Implications for relapse and dependence.

Authors:  Matthew Hearing
Journal:  Pharmacol Res       Date:  2018-11-19       Impact factor: 7.658

Review 3.  Differential roles of medial prefrontal subregions in the regulation of drug seeking.

Authors:  David E Moorman; Morgan H James; Ellen M McGlinchey; Gary Aston-Jones
Journal:  Brain Res       Date:  2014-12-18       Impact factor: 3.252

4.  Acute baclofen diminishes resting baseline blood flow to limbic structures: a perfusion fMRI study.

Authors:  Teresa R Franklin; Joshua Shin; Kanchana Jagannathan; Jesse J Suh; John A Detre; Charles P O'Brien; Anna Rose Childress
Journal:  Drug Alcohol Depend       Date:  2012-04-17       Impact factor: 4.492

5.  Remifentanil self-administration in mice promotes sex-specific prefrontal cortex dysfunction underlying deficits in cognitive flexibility.

Authors:  Eden M Anderson; Annabel Engelhardt; Skyler Demis; Elissa Porath; Matthew C Hearing
Journal:  Neuropsychopharmacology       Date:  2021-05-19       Impact factor: 8.294

Review 6.  The neurobiology of addiction: the perspective from magnetic resonance imaging present and future.

Authors:  John Suckling; Liam J Nestor
Journal:  Addiction       Date:  2016-07-25       Impact factor: 6.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.